Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Tonix Pharma ( (TNXP) ) has shared an update.
On March 24, 2025, Tonix Pharmaceuticals announced that the FDA will not require an Advisory Committee meeting for the New Drug Application of TNX-102 SL, a product candidate for fibromyalgia management. This development could streamline the approval process, potentially accelerating the product’s market entry and impacting the company’s operations and market positioning positively.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on developing innovative therapies for central nervous system disorders, immunology, and infectious diseases. Their primary product candidates include TNX-102 SL for fibromyalgia management.
YTD Price Performance: -30.17%
Average Trading Volume: 1,541,769
Technical Sentiment Signal: Buy
Current Market Cap: $148.2M
See more data about TNXP stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue